We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of anti‐factor VIII antibodies in haemophilia A subjects switching products following a provincial tender.
- Authors
Dubé, Evemie; Merlen, Clémence; Bonnefoy, Arnaud; Gauthier, Julie; Castilloux, Jean‐François; Charlebois, Janie; Cloutier, Stéphanie; Demers, Christine; Sabapathy, Christine A.; St‐Louis, Jean; Vézina, Catherine; Warner, Margaret; Rivard, Georges‐Étienne
- Abstract
Evaluation of anti-factor VIII antibodies in haemophilia A subjects switching products following a provincial tender Haemophilia A, inhibitor, recombinant factor VIII, bleeds, factor VIII usage, switching products Keywords: bleeds; factor VIII usage; haemophilia A; inhibitor; recombinant factor VIII; switching products EN bleeds factor VIII usage haemophilia A inhibitor recombinant factor VIII switching products e1 e4 4 01/13/22 20220101 NES 220101 In 2018, following a provincial tender process, most persons with haemophilia A (PWHA) in the province of Quebec (Canada) were switched to the two recombinant B-domain-truncated factor VIII (FVIII) known as Zonovate® (NovoNordisk, Mississauga, Canada) and Nuwiq® (Octapharma AG, Lachen, Switzerland) with an estimated market distribution of respectively 53% and 47%.
- Subjects
BLOOD coagulation factor VIII antibodies; HEMOPHILIA; VON Willebrand disease; BLOOD coagulation factor VIII; CHILD patients; HEMOPHILIACS; NEUTRALIZATION tests
- Publication
Haemophilia, 2022, Vol 28, Issue 1, pe1
- ISSN
1351-8216
- Publication type
Article
- DOI
10.1111/hae.14434